SVRA Feb 2025 4.000 put
- Simply Wall St.
Savara Inc.'s (NASDAQ:SVRA) high institutional ownership speaks for itself as stock continues to impress, up 14% over last week
Key Insights Institutions' substantial holdings in Savara implies that they have significant influence over the...
- Insider Monkey
Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?
We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Savara Inc. (NASDAQ:SVRA) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry has been […]
- Business Wire
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
LANGHORNE, Pa., June 28, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, for total gross proceeds of approximately $100.0 million. All of the securities to be sold in the offering are being sold by Savara. The offering included the following investo
